BCAX

Bicara Therapeutics Inc.

Price Chart

Latest Quote

$22.92

+0.97 (+4.42%)

Current Price

Previous Close	$21.95
Open	$22.22
Day High	$23.10
Day Low	$21.93
Volume	596,600

Fetched: 2026-06-18T02:06:38

Stock Information

Shares Outstanding	65.70M
Total Debt	$1.44M
Cash Equivalents	$539.75M
Net Income	$-157.32M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.51B
EPS (TTM)	$-2.77
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$903.89M
Income	$-157.32M
Book/sh	$7.84
Cash/sh	$8.21
Employees	103

Financial Ratios

Quick Ratio	13.72
Current Ratio	13.85
Debt/Eq	0.28

Returns & Margins

ROA	-21.09%
ROE	-32.34%

Ownership

Insider Ownership	10.22%
Institutional Ownership	104.19%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-6.31
P/B	2.92

Analyst Data

Recommendation	none
Target Price	$31.46

Technical Indicators

SMA20	$21.05
SMA50	$21.78
SMA200	$17.82
RSI	58.16
ATR	1.0535

Shares Float	36.65M
Short Float	21.44%
Short Ratio	19.69
Rel Volume	1.22

Performance History

Week	+13.41%
Month	+18.82%
Quarter	+24.50%
6 Months	+24.84%
YTD	+39.93%
Year	+129.20%
10 Years	-2.09%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$22.92	596,600
2026-06-16	$21.95	386,300
2026-06-15	$21.56	375,500
2026-06-12	$21.69	418,900
2026-06-11	$21.28	567,200
2026-06-10	$20.21	667,000
2026-06-09	$20.56	619,100
2026-06-08	$20.10	478,300
2026-06-05	$20.00	356,200
2026-06-04	$20.41	298,000
2026-06-03	$20.00	548,300
2026-06-02	$19.64	669,200
2026-06-01	$20.62	740,300
2026-05-29	$21.75	348,700
2026-05-28	$21.75	699,100
2026-05-27	$21.58	309,600
2026-05-26	$21.98	555,000
2026-05-22	$21.68	365,800
2026-05-21	$20.84	429,500
2026-05-20	$20.43	375,500
2026-05-19	$20.03	429,800
2026-05-18	$19.29	571,800

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

📰 Latest News

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

Motley Fool • 2026-06-13T05:21:24Z

Bicara (BCAX) Q4 2025 Earnings Transcript

Motley Fool • 2026-06-01T16:13:09Z

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

MarketBeat • 2026-05-22T15:09:40Z

A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback

Simply Wall St. • 2026-05-19T13:09:41Z

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet

Motley Fool • 2026-05-15T23:02:41Z

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Motley Fool • 2026-05-15T22:56:41Z

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

MarketBeat • 2026-05-14T21:09:08Z

Bicara Therapeutics Inc (BCAX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com • 2026-05-12T07:03:23Z

Bicara Therapeutics Inc. Common Stock Q1 2026 Earnings Call Summary

Moby • 2026-05-11T20:51:15Z

Bicara Therapeutics Q1 Earnings Call Highlights

MarketBeat • 2026-05-11T14:07:05Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$155,604,000	$82,389,000	$39,889,000	$37,656,000
Net Non Operating Interest Income Expense	$17,871,000	$14,581,000	$1,314,000	$-108,000
Operating Expense	$155,604,000	$82,389,000	$39,889,000	$37,656,000
General And Administrative Expense	$30,508,000	$18,770,000	$9,272,000	$6,344,000
Interest Expense	-	-	$0	$112,000
Other Income Expense	-	-	$-13,405,000	$-80,000
Other Non Operating Income Expenses	-	-	$-13,405,000	$-80,000
Interest Expense Non Operating	-	-	$0	$112,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-137,950,000	$-67,995,000	$-51,985,000	$-37,845,000
Net Interest Income	$17,871,000	$14,581,000	$1,314,000	$-108,000
Interest Income	$17,871,000	$14,581,000	$1,314,000	$4,000
Normalized Income	$-137,950,000	$-67,995,000	$-51,985,000	$-37,845,000
Net Income From Continuing And Discontinued Operation	$-137,950,000	$-67,995,000	$-51,985,000	$-37,845,000
Total Operating Income As Reported	$-155,604,000	$-82,389,000	$-39,889,000	$-37,656,000
Net Income Common Stockholders	$-137,950,000	$-67,995,000	$-51,985,000	$-37,845,000
Net Income	$-137,950,000	$-67,995,000	$-51,985,000	$-37,845,000
Net Income Including Noncontrolling Interests	$-137,950,000	$-67,995,000	$-51,985,000	$-37,845,000
Net Income Continuous Operations	$-137,950,000	$-67,995,000	$-51,985,000	$-37,845,000
Pretax Income	$-137,733,000	$-67,808,000	$-51,980,000	$-37,844,000
Interest Income Non Operating	$17,871,000	$14,581,000	$1,314,000	$4,000
Operating Income	$-155,604,000	$-82,389,000	$-39,889,000	$-37,656,000
Per Share
Diluted EPS	$-2.52	$-4.05	$-1.53	$-2.45
Basic EPS	$-2.52	$-4.05	$-1.53	$-2.45
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-155,499,000	$-82,333,000	$-39,870,000	$-37,722,000
Reconciled Depreciation	$105,000	$56,000	$19,000	$10,000
EBITDA (Bullshit earnings)	$-155,499,000	$-82,333,000	$-39,870,000	$-37,722,000
EBIT	$-155,604,000	$-82,389,000	$-39,889,000	$-37,732,000
Diluted Average Shares	$54,676,896	$16,805,524	$33,984,930	$15,440,460
Basic Average Shares	$54,676,896	$16,805,524	$33,984,930	$15,440,460
Diluted NI Availto Com Stockholders	$-137,950,000	$-67,995,000	$-51,985,000	$-37,845,000
Tax Provision	$217,000	$187,000	$5,000	$1,000
Research And Development	$125,096,000	$63,619,000	$30,617,000	$31,312,000
Selling General And Administration	$30,508,000	$18,770,000	$9,272,000	$6,344,000
Other Gand A	$9,926,000	$6,225,000	$9,272,000	$2,544,000
Salaries And Wages	$20,582,000	$12,545,000	$5,820,000	$3,800,000

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$401,452,000	$491,875,000	$-148,769,000	$-98,803,000
Total Assets	$430,994,000	$509,996,000	$233,982,000	$6,703,000
Total Non Current Assets	$8,941,000	$7,463,000	$2,909,000	$1,719,000
Other Non Current Assets	$6,910,000	$6,618,000	$2,094,000	$1,083,000
Current Assets	$422,053,000	$502,533,000	$231,073,000	$4,984,000
Other Current Assets	$7,252,000	$12,822,000	$633,000	$826,000
Cash Cash Equivalents And Short Term Investments	$414,801,000	$489,711,000	$230,440,000	$4,158,000
Cash And Cash Equivalents	$96,685,000	$489,711,000	$230,440,000	$4,158,000
Debt
Total Debt	$1,710,000	$738,000	$657,000	$0
Long Term Debt And Capital Lease Obligation	$593,000	$131,000	$372,000	$0
Current Debt And Capital Lease Obligation	$1,117,000	$607,000	$285,000	-
Liabilities
Total Liabilities Net Minority Interest	$29,542,000	$18,121,000	$382,751,000	$105,506,000
Total Non Current Liabilities Net Minority Interest	$593,000	$131,000	$367,666,000	$81,610,000
Current Liabilities	$28,949,000	$17,990,000	$15,085,000	$23,896,000
Payables And Accrued Expenses	$22,791,000	$14,300,000	$13,058,000	$22,720,000
Payables	$7,793,000	$4,508,000	$3,186,000	$5,137,000
Accounts Payable	$7,793,000	$4,508,000	$3,186,000	$5,137,000
Other Non Current Liabilities	-	-	$17,000	$85,000
Interest Payable	-	-	$0	$1,000
Equity
Common Stock Equity	$401,452,000	$491,875,000	$-148,769,000	$-98,803,000
Total Equity Gross Minority Interest	$401,452,000	$491,875,000	$-148,769,000	$-98,803,000
Stockholders Equity	$401,452,000	$491,875,000	$-148,769,000	$-98,803,000
Gains Losses Not Affecting Retained Earnings	$243,000	$0	-	-
Other Equity Adjustments	$243,000	-	-	-
Retained Earnings	$-358,966,000	$-221,016,000	$-153,021,000	$-101,036,000
Preferred Securities Outside Stock Equity	-	$0	$367,277,000	$81,525,000
Other
Ordinary Shares Number	$56,600,724	$54,440,013	$51,760,925	$51,760,925
Share Issued	$56,600,724	$54,440,013	$51,760,925	$51,760,925
Tangible Book Value	$401,452,000	$491,875,000	$-148,769,000	$-98,803,000
Invested Capital	$401,452,000	$491,875,000	$-148,769,000	$-98,803,000
Working Capital	$393,104,000	$484,543,000	$215,988,000	$-18,912,000
Capital Lease Obligations	$1,710,000	$738,000	$657,000	$0
Total Capitalization	$401,452,000	$491,875,000	$-148,769,000	$-98,803,000
Additional Paid In Capital	$760,168,000	$712,884,000	$4,250,000	$2,231,000
Capital Stock	$7,000	$7,000	$2,000	$2,000
Common Stock	$7,000	$7,000	$2,000	$2,000
Preferred Stock	$0	$0	$0	-
Long Term Capital Lease Obligation	$593,000	$131,000	$372,000	$0
Current Capital Lease Obligation	$1,117,000	$607,000	$285,000	$0
Pensionand Other Post Retirement Benefit Plans Current	$5,041,000	$3,083,000	$1,742,000	$1,176,000
Current Accrued Expenses	$14,998,000	$9,792,000	$9,872,000	$17,583,000
Net PPE	$2,031,000	$845,000	$815,000	$636,000
Gross PPE	$2,031,000	$845,000	$815,000	$636,000
Other Properties	$2,031,000	$845,000	$815,000	$636,000
Other Short Term Investments	$318,116,000	$0	-	-

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-107,114,000	$-74,822,000	$-46,214,000	$-32,268,000
Operating Activities
Operating Cash Flow	$-106,834,000	$-74,751,000	$-45,628,000	$-32,076,000
Cash Flow From Continuing Operating Activities	$-106,834,000	$-74,751,000	$-45,628,000	$-32,076,000
Investing Activities
Capital Expenditure	$-280,000	$-71,000	$-586,000	$-192,000
Investing Cash Flow	$-318,453,000	$-9,000	$-586,000	$-192,000
Cash Flow From Continuing Investing Activities	$-318,453,000	$-9,000	$-586,000	$-192,000
Financing Activities
Issuance Of Capital Stock	$29,498,000	$332,427,000	$272,347,000	$31,535,000
Financing Cash Flow	$32,261,000	$334,031,000	$272,496,000	$31,695,000
Cash Flow From Continuing Financing Activities	$32,261,000	$334,031,000	$272,496,000	$31,695,000
Net Common Stock Issuance	$29,498,000	$332,427,000	$0	-
Common Stock Issuance	$29,498,000	$332,427,000	$0	-
Net Preferred Stock Issuance	-	$0	$272,347,000	$31,535,000
Preferred Stock Issuance	-	$0	$272,347,000	$31,535,000
Other
End Cash Position	$96,685,000	$489,711,000	$230,440,000	$4,158,000
Beginning Cash Position	$489,711,000	$230,440,000	$4,158,000	$4,731,000
Changes In Cash	$-393,026,000	$259,271,000	$226,282,000	$-573,000
Proceeds From Stock Option Exercised	$2,763,000	$1,604,000	$149,000	$160,000
Net Investment Purchase And Sale	$-318,173,000	$0	-	-
Purchase Of Investment	$-318,173,000	$0	-	-
Net PPE Purchase And Sale	$-280,000	$-9,000	$-586,000	$-192,000
Sale Of PPE	$0	$62,000	$0	-
Purchase Of PPE	$-280,000	$-71,000	$-586,000	$-192,000
Change In Working Capital	$14,809,000	$-14,132,000	$-9,624,000	$4,949,000
Change In Other Current Liabilities	$-932,000	$81,000	$-47,000	$0
Change In Payables And Accrued Expense	$10,460,000	$2,637,000	$-8,663,000	$5,871,000
Change In Prepaid Assets	$5,281,000	$-16,850,000	$-914,000	$-922,000
Other Non Cash Items	$895,000	$-77,000	$13,495,000	-
Stock Based Compensation	$15,006,000	$7,397,000	$1,899,000	$810,000
Amortization Of Securities	$301,000	$0	-	-
Depreciation Amortization Depletion	$105,000	$56,000	$19,000	$10,000
Depreciation And Amortization	$105,000	$56,000	$19,000	$10,000
Depreciation	$105,000	$56,000	$19,000	$10,000
Net Income From Continuing Operations	$-137,950,000	$-67,995,000	$-51,985,000	$-37,845,000
Asset Impairment Charge	-	$0	$568,000	$0
Income Tax Paid Supplemental Data	-	-	$0	$1,000

Fetched: 2026-06-16